106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2017 All rights reserved
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be
considered exclusive of other methods of care reasonably directed at obtaining the same results. e
ultimate judgment concerning the propriety of any course of conduct must be made by the clinician
aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
AAAAISUB17032a
Source
Greenhawt M, Oppenheimer J, Nelson MN, et al. Sublingual immunotherapy. Ann Allerg y
Asthma Immunol. 2017;118(3):276-282.e2.
Abbreviations
AC, allergic conjunctivitis; ACE, angiotensin-converting enzyme; AIT, allergen immunotherapy;
AR, allergic rhinitis; FDA, US Food and Drug Administration; GI, gastrointestinal; IFN-γ,
interferon γ; IL, interleukin; MedDRA, Medical Dictionary for Regulatory Activities; NSAIDs,
nonsteroidal anti-inflammatory drugs; OAS, oral allerg y syndrome; SCIT, subcutaneous
immunotherapy; SLIT, sublingual immunotherapy; SS, summary statement
Strength of Recommendation and Quality of Evidence
Strength of Recommendation Quality of Evidence
S Strong: Benefit clearly
exceeds harm
A / B Directly based on category I–II evidence
M Moderate: Benefit
exceeds harm but
quality of evidence is
not as strong
B / C Directly based on category II–III evidence or
extrapolated recommendation from category I
evidence
W Weak: Quality of
evidence is suspect
or there is little clear
advantage to one
approach vs. another
D Directly based on category IV evidence or
extrapolated recommendation from category I, II,
or III evidence
